Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries.
The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’.
Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.
The company’s manufacturing facilities are loaced at Indrad, Dahej, Baddi, Sikkim Unit I & II, Sikkim Unit III, Vizag, Pithampur, Levittown Pennsylvania and HSE Forum.
1984-85 Received Chemexcil Export Award
1984-85 Received Udyog Ratna Award
1985-86 Received Chemexcil Export Award
1986-87 Received Chemexcil Export Award
1986-87 Received IDMA Quality Excellence Award
1986-87 Received Export Award from Govt. of Gujarat
1987-88 Received Export Award from Govt. of Gujarat
1989-90 Received Chemexcil Trishul Award for highest Pharma Exports
1989-90 Received IDMA Quality Excellence Award
1988-89 Received Chemexcil Export Award
1990-91 Received Export Award from Govt. of Gujarat
1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship
1991-92 Received Export Award from Govt. of Gujarat
1991-92 Received National Export Award
1992-93 Received IDMA Quality Excellence Award
1999-00 GCCI Export Appreciation Award
1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.
2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility
2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
2009-10 Baddi Plant awarded Five Star rating by British Safety Council
2012-13 Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
2017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
1959: U. N. Mehta started Pharma operations.
1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.
1980: First manufacturing facility set up at Vatva in Ahmedabad
1983: Entry into the international markets. First Export order to USSR received
1984: Torrent Laboratories Limited received Chemexcil Export Award.
1984: Torrent Laboratories Limited received Udyog Ratna Award.
1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.
1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.
1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.
1985: Torrent Laboratories Limited received Chemexcil Export Award.
1986: Torrent Laboratories Limited received Chemexcil Export Award.
1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.
1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.
1987: Torrent Laboratories Limited received Chemexcil Export Award.
1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.
1989: Second manufacturing plant commissioned at Indrad
1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.
1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
1988: Torrent Laboratories Limited received Chemexcil Export Award.
1990: Torrent Exports Limited received National Export Award.
1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.
1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
1995: Torrent Gujarat Biotech Limited plant commissioned.
1996: U N Mehta bestowed with the title of Corporate Business Man of the Year
1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.
1998: State-of-the-art R&D Centre commissioned.
1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.
1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.
1999: First New Chemical Entity Patented by Torrent Research Center
1999: GCCI Export Appreciation Award
1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.
2000: Indrad Plant received ISO 9001:2000 Certificate
2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).
2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation
2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility
2001: Torrent do Brasil Ltda. set up in Brazil
2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.
2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:1999
2002: Torrent's R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002:
2002: Board for Testing and Calibration Laboratories (NABL).
2002: Addition of a new marketing division, MIND
2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)
2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
2002: Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
2003: Torrent Pharma Inc. set up in USA.
2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant
2003: Torrent Pharma Philippines Inc. set up.
2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals
2004: Restructuring of marketing divisions and addition of new division, Delta.
2004: Torrent Australasia Pty Ltd. incorporated in Australia
2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.
2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.
2005: Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany.
2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.
2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL
2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval
2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products
2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body
2007: Construction of Sikkim Plant started
2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany
2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market
2009: Baddi Plant awarded Five Star rating by British Safety Council
2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda
2010: An advanced facility for Stability Studies set up at Indrad Plant
2010: Entered into the therapeutic area of Gynaecology
2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico
2010: Started construction of Dahej manufacturing facility
2010: Commissioned a subsidiary in United Kingdom and Romania
2010: Torrent Research Center develops Long Acting Injectables technology
2010: Foray into oncology segment
2011: Sikkim Plant commences operation
2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center
2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment
2012: Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
2012: Topical Foams system developed by Torrent Research Center
2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal
2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment
2014: Torrent Pharma's Dahej Plant commences operations
2015: Torrent acquires 100% stake of Zyg Pharma
2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
2016: Dahej Plant receives USFDA approval
2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited
2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.
2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
2017: Acquired Women Healthcare brands from Novartis
2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
2019: Torrent & Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India
Comment